On February 4, 2025 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that the Company will deliver a corporate presentation at the BIO CEO & Investor Conference (Press release, Soligenix, FEB 4, 2025, View Source [SID1234650034]). The conference will be held February 10 – 11, 2025 in New York, N.Y. For more information about the BIO CEO & Investor Conference, please refer to the conference website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registered conference attendees may schedule one-on-one meetings with Soligenix management via the conference scheduling platform. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected].